Skip to main content
. 2013 Mar 24;2013:846740. doi: 10.1155/2013/846740

Figure 3.

Figure 3

Hypothetical scheme shows the inhibitory signaling of andrographolide in platelet activation. Andrographolide can activate the endothelial nitric oxide synthase- (eNOS-) NO-cyclic GMP pathway, followed by the inhibition of both the PLCγ2-DAG-PKC and PI3 kinase/Akt cascades, and ultimately inhibits platelet aggregation [120].